Only 1 country fully self-sufficient without global food trade
Researchers are assessing food self-sufficiency of countries around the world if food imports and exports between countries suddenly stopped. (Envato Elements pic)
PARIS : What would happen if food imports and exports between countries suddenly stopped? Researchers have looked at this hypothetical situation to assess the food self-sufficiency of countries around the world.
According to their estimates, only one nation would be able to feed its population in seven food categories if this catastrophic scenario were to occur.
Published in the journal Nature Food, the study was conducted by researchers from the University of Göttingen (Germany) and the University of Edinburgh (Scotland).
They used data from the Food and Agriculture Organisation of the United Nations (FAO) to assess the ability of 186 countries to supply themselves with legumes, nuts and seeds, vegetables, fruit, starchy foods, dairy products, meat, and fish.
Taking these seven major food categories into account, only one country on the list would be capable of self-sufficiency, ie, capable of providing food for its inhabitants across all seven categories without depending on other countries. This is Guyana, a South American country with a population of around 800,000.
Next come China and Vietnam, which would be able to supply themselves with six out of seven food categories. Out of 186 countries, 154 can meet the requirements of two to five of the seven food groups.
But overall, the picture is worrying.
Only one country in seven is self-sufficient in five or more food groups. Most of these nations are located in Europe and South America.
The other countries have low production and depend almost exclusively on a single trading partner for more than half of their imports.
'Low self-sufficiency and overdependence on a few countries for imports threaten their capability to respond to global shocks, particularly for small states,' the report stated. Worse still, some countries are unable to achieve self-sufficiency in any of the food groups studied. This is the case in Afghanistan, the United Arab Emirates, Iraq, Macao, Qatar, and Yemen.
Establishing more resilient supply chains
This finding is all the more alarming given the recent restrictions imposed by the United States since Donald Trump returned to power in January 2025.
'International food trade and cooperation is essential for healthy and sustainable diets. However, heavy reliance on imports from single countries can leave nations vulnerable.
'Building resilient food supply chains is imperative for ensuring public health,' cautioned the study's first author, Jonas Stehl, a researcher at the University of Göttingen, quoted in a news release.
The need for nations to be self-sufficient is also crucial in tackling the climate crisis. While a large majority of European countries overproduce meat and dairy products, demand for these foods is very low in African countries.
Less than half of countries produce enough foods such as beans and peas, as well as nuts and seeds, while only a quarter produce enough vegetables to meet domestic demand.
'Climate shocks are reshaping the agriculture sector and will continue to intensify. Open trade and innovation are essential to secure healthy, low-carbon diets,' said study co-author, Alexander Vonderschmidt, PhD researcher at the University of Edinburgh's Division of Global Agriculture and Food Systems.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
2 days ago
- Malay Mail
Smarter ponds, greener future: The UM robot changing Malaysian fish farming — Nuradila Zahirah Mohd Azmi
JUNE 19 — In the quiet townships of Pahang, something remarkable is happening beneath the still surface of fish ponds. Where once farmers relied entirely on manual labour to clean water and monitor quality, a new innovation is gliding across the pond — powered not by fuel, but by the sun. This is AquaRover — a solar-powered robotic water cleaner developed by a research team at Universiti Malaya (UM), led by Dr Archina Buthiyappan, a senior lecturer and researcher with a passion for merging technology with sustainability. Designed to help fish farmers manage water quality more efficiently, the robot is not only making waves in aquaculture but also contributing to Malaysia's broader food security and green technology agenda. 'Our aim was to solve multiple pain points at once — water quality, labour shortages, operational costs — all while keeping sustainability at the core,' says Dr Archina. 'AquaRover was born from that ambition.' Dr Archina with students of SMK Methodist ACS Klang. The floating innovation Aquaculture plays a vital role in Malaysia's food supply chain. But fish farmers have long struggled with recurring challenges: polluted water, algae blooms, disease outbreaks, and the rising cost of manpower. After engaging directly with fish farmers on the ground, Dr Archina and her team began designing a solution tailored to their daily realities. The result was a floating robot capable of autonomously cleaning pond surfaces by removing organic waste, algae, and leftover feed. Unlike traditional fuel-powered machines, AquaRover runs on solar energy — offering a greener, cost-saving alternative. But it doesn't just clean. Equipped with high-precision sensors, AquaRover also monitors critical water parameters such as pH, temperature, and ammonia levels. This real-time data allows farmers to take early action to prevent disease, reduce fish stress, and optimise feeding schedules — all of which translate into healthier fish and higher yields. Backed by RM222,000 in funding from the Komuniti@UniMADANI grant under the Ministry of Finance, the AquaRover prototype was put to the test at several hatcheries in Pahang. The results were immediate and striking. Farmers reported clearer pond water, improved fish growth, and fewer disease incidents. Feed conversion rates improved, allowing farmers to use less feed for better output. The reduction in manual cleaning not only saved time and cost, but also lessened the physical burden on workers. 'When the farmers saw how much clearer the water became — and how consistent the sensor readings were — the trust grew quickly,' explains Dr Archina. 'We also made design adjustments based on their feedback. This wasn't built in a lab bubble — it was shaped by the community.' The AquaRover prototype was put to the test at several hatcheries in Pahang. From hatcheries to classrooms and beyond Beyond commercial application, the project has also found a place in education. As part of a wider outreach initiative, the team brought AquaRover to secondary schools in Selangor, using it as a real-world teaching tool to spark interest in science, robotics, and environmental stewardship. Students from SMK Bandar Baru Sungai Long and SMK Methodist ACS in Klang were introduced to the technology through hands-on demonstrations. They learned how robotics, sustainability, and agriculture can come together to solve real-world challenges — planting seeds of curiosity that may one day grow into careers in STEM and innovation. The success of AquaRover has caught the attention of government agencies and industry players alike. With growing concern over climate change, food security, and rural livelihoods, this solar-powered robot offers a rare combination of high-tech precision and practical value. Dr Archina believes that the true impact of AquaRover extends beyond the ponds of Pahang. 'What we're building is not just a robot — but a new mindset for how we approach agriculture in a warming world. Clean energy, smart systems, and local input must go hand in hand.' As Malaysia looks to future-proof its agricultural sector, innovations like AquaRover offer a compelling glimpse of what's possible when research is grounded in community needs and driven by sustainable thinking. * Nuradila Zahirah Mohd Azmi is a postgraduate researcher at the Faculty of Science, Universiti Malaya. Further details about the innovation may be acquired from Dr Archina Buthiyappan via email at [email protected] ** This is the personal opinion of the writer or publication and does not necessarily represent the views of Malay Mail.
Malay Mail
3 days ago
- Malay Mail
Hong Kong Baptist University and Elsevier Report Highlights Global Expansion of Chinese Medicine Research, Urges Standardised Frameworks for Broader Integration
HKBU and Elsevier launched a new report "Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine", highlighting the growing global impact of Chinese Medicine research in diversified healthcare solutions. Rapid expansion : Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. : Chinese Medicine research grew at a 10.6% compound annual growth rate — more than double the global research average — nearly tripling output between 2014 and 2023. High scholarly impact : 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. : 14.2% of Chinese Medicine papers ranked among the world's top 10% most-cited (global norm: 10%), with a field-weighted citation impact (FWCI) of 1.12. Interdisciplinary breadth : Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. : Medicine dominates (61.9% of output), followed by Biochemistry, Genetics & Molecular Biology (33.1%) and Pharmacology (28.1%). Citing publications span diverse major domains — from Engineering to Materials Science. Global collaboration hubs : Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. : Hong Kong SAR and Macao SAR exceed 80% cross-regional collaboration, above the 18% world average, and achieving FWCI >1.6 in cross-regional collaborative publications. Emerging research foci : Top-published trending topics include "Herbaceous Agent | Chinese Medicine | Network Pharmacology" and COVID-19 applications, reflecting integration of omics, AI and systems methods. : Top-published trending topics include "Herbaceous Agent | Chinese Medicine | Network Pharmacology" and COVID-19 applications, reflecting integration of omics, AI and systems methods. Societal resonance: 11.1% of research outputs were mentioned on social media and 2.9% cited in policy documents, reflecting growing public and policymaker interest. ISTANBUL, TURKEY - Media OutReach Newswire - 18 June 2025 – The report "Evolving Legacy: Decoding the Scientific Trajectory of Chinese Medicine" released today by Hong Kong Baptist University (HKBU) and Elsevier, reveals the growing impact of Chinese Medicine research on global healthcare and modern health challenges. In this context, "Chinese Medicine research" encompasses not only clinical practice, but also basic and translational science, AI-driven systems medicine, and the network pharmacology of herbal formulas. This first bibliometric analysis of Chinese Medicine research from 2014 to 2023 highlights the field's rapid growth, interdisciplinarity, and societal impact on Digital Health and Systems findings from the report include:Chinese Medicine's mainstream integration lacks a global, transparent, evidence-based framework. To elevate its scientific profile, key strategies include developing internationally accepted clinical guidelines through expert consensus, enhancing trial reporting standards to improve research quality, and fostering interdisciplinary, cross-regional collaboration to drive innovation and systemic impact."'Evolving Legacy' demonstrates how Chinese Medicine research has matured into a global, evidence-informed field," said"We envision a future where data science and AI illuminate what Chinese Medicine research has long intimated, providing deeper insights into health classifications and compound interventions. The next frontier is using Chinese Medicine research to uncover insights possibly overlooked in Digital Health and Systems Medicine, strengthening their scientific foundation and impact.""This report offers unprecedented insights into Chinese Medicine's evolving scientific landscape," added. "It illuminates the growing global impact of Chinese Medicine research and its role in diversified healthcare solutions, making a vital step towards bridging traditional knowledge with modern validation for the benefit of global health."The report was developed using Elsevier's bibliometric tools, Scopus and SciVal, based on a comprehensive dataset and case studies compiled in collaboration with HKBU Chinese Medicine research experts. The report can be accessed on Hashtag: #HKBU The issuer is solely responsible for the content of this announcement.
New Straits Times
3 days ago
- New Straits Times
China pharma projects disrupted by Sino-US tensions
SHANGHAI: Drug research and development firms in China including WuXi AppTec and WuXi Biologics are changing project plans, stockpiling supplies and discussing testing locally, said sources with knowledge of the matter, as they seek to mitigate the impact of US-China trade tensions. China's sprawling pharmaceutical research and manufacturing sector serves global drug giants such as Pfizer and AstraZeneca with a low-cost development model that often uses imported clinical samples, equipment, chemicals and other materials to conduct work. Fears of delay in access to US supply chains and raised import tariffs are spurring biotech and pharmaceutical companies to avoid, pause or consider delaying the start of projects, according to three sources. They are also discussing testing US clinical samples in the US, instead of sending them to China for further research, a move that could increase costs, and requesting additional supplies for backup, three other sources said. The six sources who spoke to Reuters are director or executive-level employees involved in various aspects of the industry in China including research and development, manufacturing and supply chains. All but two agreed to speak only on condition of anonymity because of concerns about effects on fundraising plans or they were not authorised to speak to media. The developments have not been reported previously. US and Chinese officials said last week they had agreed on a framework to put a May trade truce back on track and remove China's export restrictions on rare earths, but offered little sign of a durable resolution to longstanding trade differences that have affected products ranging from semiconductors and jet engines to medical equipment and pharmaceuticals. "What kind of long-term policy it could be, you know, what kind of tariff would it be in half a year, in one year... nobody knows. And that's the problem. That's what makes everybody worry and nervous," said Chen Gong, co-founder of NeuExcell Therapeutics, a biotech with its main operations in Suzhou. He said the US-China trade tensions had made him more cautious about investing in a clinical trial and the company would delay its start if it did not have sufficient funding. Reliance on US imports has come into particular focus as trade tensions escalate. In 2024, the US exported diagnostic and laboratory reagents to China valued at about US$1.4 billion and prepared culture media for the development or maintenance of microorganisms worth about US$125 million, U.N. Comtrade data showed. In a sign of the importance of some of the imports and the damaging effect disruption could have on China's healthcare industry, some US-made goods including diagnostic reagents from Germany's Siemens Healthineers were exempted from raised Chinese tariffs, that company said in May. China raised its tariffs on US imports to as much as 125 per cent though it has since reduced that to 10 per cent while it works out a more permanent trade deal. HIGHER COSTS, DELAYS WuXi AppTec and a Chinese biotechnology firm that was its research client agreed in May to switch US-made reagents they had been using for a Hepatitis B virus pre-clinical research project into non-U.S. versions due partly to concerns about higher costs from tariffs, a source at the client company said. The project had been temporarily paused during the discussions, which began prior to May, the source said. WuXi AppTec said it makes "every effort to avoid disruptions or delays in the delivery of services to customers." Since April, at least 17 Chinese biotech and pharmaceutical clients have contacted Chinese cell culture media manufacturer JS Biosciences asking it to keep locally-made backup raw materials for production because they were concerned about cost increases or the inability to access foreign supplies, the firm's CEO Luo Shun said. "If they have a product made by us, and we rely on the foreign raw material supply and that raw material will increase in price or is never going to come, obviously it will impact their manufacturing of those life-saving drugs. So obviously, that's their primary concern," Luo said. Another Chinese drug research and development firm decided not to provide a quotation to a foreign pharmaceutical company interested in hiring it for protein drug manufacturing, due to delays in obtaining necessary US-made culture medium from a US subsidiary of Japan's Fujifilm, a source at the Chinese firm said. The potential client would likely not have accepted waiting on imports of new supplies into China, which would typically take two to four months, the source said. A Fujifilm Holdings America Corporation spokesperson said Fujifilm Biosciences, one of its life science business units, has made significant investments to build a robust global manufacturing network so that it could navigate any challenges or disruptions, without elaborating on its supply issue involving China. STOCKPILING, US TESTING After China announced a large rise in tariffs for US imports in April, WuXi Biologics placed a bigger-than-normal order for reagents made in the US with a supplier because it was not sure how long that policy action would continue, said a source at the supplier. WuXi Biologics did not respond to requests for comment. Concerns about the potential for US export restrictions led China's Innovent Biologics and multinational BeOne Medicines to discuss with Massachusetts-headquartered Thermo Fisher Scientific the prospect of not sending US clinical samples to China, said a source at the US company. Testing US samples in-country instead of in China would be more expensive, the source said.
